What is Drug Response Profiling?
Drug response profiling (DRP) is an ex vivo functional assay to support personalized treatment decisions for children suffering from high-risk hematological and solid tumor. Using an automated screening platform DRP tests the viability of patient cancer cells upon exposure to a panel of chemotherapeutics and molecularly targeted agents providing direct feedback about the efficacy of a particular medicine on the patient’s tumor cells.
Who may benefit from DRP?
DRP helps clinicians prioritize limited treatment options for patients with relapsed / refractory disease. Situations where DRP can support treatment decisions include:
- Patients with primary refractory disease or relapse with the intent to bridge to HSCT / CAR-T
- Salvage therapy with targeted drug combinations
Federated Relapsed/Refractory Acute Leukemia Board
DRP results of pediatric patients with acute lymphoblastic leukemia are discussed in concert with insights from genetic screening and routine diagnostics in an interdisciplinary leukemia board. This biweekly forum brings together the European leaders on clinical trials, treating physicians and laboratory specialists to exchange expertise and prioritize actionable treatment options for the patients.
Get in touch
If you would like to refer your patient for drug profiling please reach out to our DRP-Team.
